J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
PR NewswireJun 10, 2024
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, during the 3rd of June poster session of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held at McCormick Place in Chicago, USA, from May 31 to June 4. Professor Cho, Byoung Chul posing with the JIN-A02 poster at the 2024 ASCO Chicago USA This latest study update of JIN-A02 reported anothe